ArticleNorthern clinics of Istanbul2025
Severe cutaneous adverse drug reactions due to antituberculosis drugs and their management.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of long non-coding RNA HCP5 in ulcerative cutaneous tuberculosis therapy introduction.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTuberculosis and drug reactions due to antituberculosis drugs are important public health problems. Severe cutaneous adverse drug reactions (SCARs) due to antituberculosis drugs are factor that makes tuberculosis treatment difficultchallenging. In this real-life study, we present our experience with SCARs due to antituberculosis drugs and their management.
methodsPatients hospitalized in the tuberculosis ward of tertiary care reference hospital between January 1, 2015, and September 1, 2023, were retrospectively reviewed. Patients who consulted the immunology and allergy clinic were included in the study.
resultsA total of 4,039 patients were hospitalized with tuberculosis during the study period. A total of 316 (7.8%) patients were consulted, and out of these, eight (2.5%) patients were evaluated as SCARs. Of the eight patients, seven (87.5%) were diagnosed with drug reaction with eosinophilia and systemic symptoms (DRESS), and one was diagnosed with Stevens-Johnson syndrome (SJS) (12.5%). The peripheral blood eosinophil count of patients with DRESS ranged between 740 and 8,690 cells/µL. One patient tested positive for human immunodeficiency virus and developed SJS. Methylprednisolone intravenous 1 mg/kg and Fexofenadine 180 mg/day per oral were used in the treatment of SCARs in all cases. Ad-on treatment for three cases used mepolizumab (anti-IL5 monoclonal antibody) for DRESS. All patients were switched to an alternative treatment protocol and tolerated the new regimen well.
conclusionIn cases with developed SCARs, a new treatment protocol consisting of different medications can be applied after the symptoms improve. DRESS was the most common SCAR of antituberculosis drugs. Monitoring the eosinophil count can help in early diagnosis. Systemic steroids and antihistamines may be effective in the treatment. Mepolizumab can be used with off-label approval in the treatment of DRESS cases to accelerate the treatment process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.